Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn's disease.

Mottawea W, Chiang CK, Mühlbauer M, Starr AE, Butcher J, Abujamel T, Deeke SA, Brandel A, Zhou H, Shokralla S, Hajibabaei M, Singleton R, Benchimol EI, Jobin C, Mack DR, Figeys D, Stintzi A. · 2016

Read Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn's disease. by Mottawea W, Chiang CK, Mühlbauer M, Starr AE, Butcher J, Abujamel T, Deeke SA, Brandel A, Zhou H, Shokralla S, Hajibabaei M, Singleton R, Benchimol EI, Jobin C, Mack DR, Figeys D, Stintzi A. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5122959.txt.

Introduction

Walid Mottawea and a large team of co-authors probed the roots of Crohn's disease in Nature Communications in 2016. Crohn's brings chronic gut inflammation, and gut microbe imbalance is linked to it, but cause and effect were unclear. They studied newly diagnosed children, before treatment could blur the picture.

The patients' gut proteins pointed to weakened mitochondria, the cells' power units, with proteins that detoxify hydrogen sulfide turned down while sulfide-making microbes rose. One microbe, Atopobium parvulum, sat at the center of the sulfide producers' network. In susceptible mice it triggered gut-wide inflammation that needed other microbes present, and a sulfide-scavenging drug eased it. The work ties a specific microbe and a toxic gas to Crohn's mechanism.

Catalog record

CREATORMottawea W, Chiang CK, Mühlbauer M, Starr AE, Butcher J, Abujamel T, Deeke SA, Brandel A, Zhou H, Shokralla S, Hajibabaei M, Singleton R, Benchimol EI, Jobin C, Mack DR, Figeys D, Stintzi A.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE92 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5122959

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Altered intestinal microbiota–host mitochondria crosstalk in new onset Crohn's disease By Walid Mottawea, Cheng-Kang Chiang, Marcus Mühlbauer, Amanda E Starr, James Butcher, Turki Abujamel, Shelley A Deeke, Annette Brandel, Hu Zhou, Shadi Shokralla, Mehrdad Hajibabaei, Ruth Singleton Published in: Nature Communications DOI: 10.1038/ncomms13419 ABSTRACT Abstract Intestinal microbial dysbiosis is associated with Crohn's disease (CD). However, the mechanisms leading to the chronic mucosal inflammation that characterizes this disease remain unclear. In this report, we use systems-level approaches to study the interactions between the gut microbiota and host in new-onset paediatric patients to evaluate causality and mechanisms of disease. We report an altered host proteome in CD patients indicative of impaired mitochondrial functions. In particular, mitochondrial proteins implicated in H2S detoxification are downregulated, while the relative abundance of H2S microbial producers is increased. Network correlation analysis reveals that Atopobium parvulum controls the central hub of H2S producers. A. parvulum induces pancolitis in colitis-susceptible interleukin-10-deficient mice and this phenotype requires the presence of the intestinal microbiota. Administrating the H2S scavenger bismuth mitigates A. parvulum-induced colitis in vivo. This study reveals that host–microbiota interactions are disturbed in CD and thus provides mechanistic insights into CD pathogenesis. Inflammatory bowel disease (IBD) is characterized by chronic and relapsing mucosal inflammation of the gastrointestinal tract and comprises two main subtypes, Crohn's disease (CD) and ulcerative colitis (UC)1. A prevailing hypothesis is that IBD development is a consequence of aberrant interplay between an altered intestinal microbiota with the host2. The composition of the intestinal microbiota from IBD patients is typically characterized by decreased prevalence of protective microorganisms (that is, Clostridium XIVa and IV groups) and an expansion of detrimental bacteria (that is, Enterobacteriaceae and Fusobacteria)2,3,4,5,6,7. However, there is limited information on causality and mechanism of disease. Moreover, a fundamental unanswered question is whether the observed microbial dysbiosis is a cause or a consequence of inflammation. To address causality and microbial dysbiosis in CD pathogenesis, we conducted a systems-level study of the interaction between the intestinal microbiota and host at the mucosa–luminal interface (MLI) in newly diagnosed paediatric patients. New-onset, paediatric subjects constitute an important population to study the role of the intestinal microbiota in IBD as there are no treatment effects on the disease process, co-morbidities are rare and there are fewer confounders as compared with adults. In addition, the inflammatory phase of IBD characteristically predominates in younger subjects and thus, these patients are more likely to reveal the underlying mechanisms that promote early development of disease. To further identify key microbial drivers of inflammation, we characterized the MLI microbial community at the time of diagnostic endoscopy. In contrast to stool microbiota, the MLI microbial community is in direct contact with the site of inflammation and is therefore likely to be directly involved in the initiation and maintenance of the diseased state. To understand the interactions between the intestinal microbiome and the host, we characterized the host proteome and identified key associations between the host proteome and intestinal microbiota. We also validated the causative role of a microbe that predicts disease severity in a mouse model of colitis. The use of these approaches in the context of a phenotypically well-defined patient cohort has enabled us to elucidate a possible mechanism of disease and to identify key microbial drivers of inflammation. RESULTS Characteristics of the paediatric IBD gut microbiota Although others have previously characterized the microbiota composition at the mucosa-luminal interface (MLI) in adult cohorts8,9, the MLI of new-onset paediatric IBD patients has not been previously reported. Given the intimate location of the MLI microbiota on the host intestinal epithelium, we hypothesized that studying the microbial composition at this location would provide direct information on how microbes affect inflammation and gut physiological processes. To characterize the composition of the MLI microbiota in IBD, we collected the MLI from the ascending colon of new-onset paediatric IBD patients and controls by flushing sterile water onto the mucosa to dislodge the mucus layer from the mucosal epithelial cells followed by aspiration of these mucosal lavages through the colonoscope (Table 1 and Supplementary Table 1). We investigated the MLI microbiota using 16S rDNA-based Illumina sequencing on a total of 65 CD, 21 UC patients and 42 control subjects with the remaining samples from our cohort (29 CD, 16 UC and 21 controls) used for independent validation with alternative quantification approaches (that is, Ion Torrent/454 sequencing and quantitative PCR (qPCR)). Microbial diversity was unchanged between controls and the CD/UC patients (Fig. 1a and Supplementary Figs 1 and 2) in contrast to the current model of decreased diversity in IBD patients10, but in agreement with a previous study on new-onset paediatric IBD patients3. These results suggest that first-onset paediatric patients have a distinct microbial profile as compared with adults and post-treatment cohorts. [Table: Subjects characteristics.] [Figure: Assessment of the microbiota composition at the mucosa-luminal interface of new-onset paediatric IBD.(a) Diversity of the intestinal microbiota in control and CD paediatric patients as a function of disease severity. Shannon index was calculated using 500,000 reads per sample. Crosses indicate the mean while horizontal lines indicate the median. (b) Histogram of linear discriminant analysis (LDA) effect size score for CD differentially abundant taxa compared with controls (n=65 and 42 for CD and controls, respectively); only OTUs meeting an LDA significant threshold ≥2 with a P<0.05 (pairwise Wilcoxon test) are shown and are denoted with their lowest defined taxonomy. (c) Phylogenetic tree of the differentially abundant OTUs identified by metagenomeSeq analysis (fold change ≥2 and P<0.05); an increasing red intensity indicates OTUs whose relative abundance increased, whereas an increasing blue intensity indicates OTUs whose relative abundance decreased in CD patients with severe inflammation as compared with mild (outer circle) or severe as compared with moderate (inner circle); the maximum colour output for this figure was set at a Log2 value of ±3. (d) The qPCR quantification of butyrate producing bacteria in control and CD microbiota. Butyryl-CoA: acetyl-CoA transferase gene (BCoAT); n=20 and 34 for control and CD, respectively; statistical comparison by Mann–Whitney two-tailed test; **P<0.01). (e) Log2 sum of rarefied reads assigned to taxa known to produce H2S through amino acid fermentation were plotted for the control and as a function of CD severity (n=39, 11, 11, 43 for control subjects and mild, moderate and severe CD, respectively). (f) The qPCR quantification of sulfate reducing bacteria in control and CD patient microbiota as a function of disease severity. Dissimilatory sulfide reductase gene (DSR); n=16, 9, 9 and 8 for control, mild, moderate and severe CD, respectively). (a,e,f) Statistical comparison by Kruskal–Wallis test using Dunn's post hoc test and followed by a Bonferroni correction for the significance level; *P<0.05; **P<0.01. Crosses indicate the mean while horizontal lines indicate the median.] Phylotypes differentially abundant between CD and controls or UC and controls were identified using a linear discriminant analysis effect size method11 and a zero-inflated Gaussian mixture model (metagenomeSeq)12. These two statistical methods identified most of the same key microbes (Fig. 1b and Supplementary Fig. 3; and Supplementary Data 1 and 2). In addition, to ensure that our use of the V6 hypervariable region as opposed to the V4 region commonly used in microbiota studies did not unduly influence our results, we sequenced the V4 and V6 regions in a subset

Read the complete text